NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Dren Bio

Dren Bio

Private
San Carlos, CaliforniaHealthcare & Life Scienceshttps://drenbio.com/

Last Round

Corporate Funding

Jul 24, 2024

Total Funding Raised

$156M

Company Overview

Dren Bio is a biotechnology company that develops therapeutic antibodies designed to selectively target and deplete pathogenic cells and disease-causing agents for the treatment of cancer, autoimmune disorders, and other serious diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biopharmaceuticalmonoclonal antibodybispecific antibodydrug discoveryautoimmune diseaseoncologyclinical-stage biotechtargeted therapyantibody engineeringbiologicspharma licensingprecision medicinetherapeutic pipelinedrug development

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Dren Bio Comparables

Compare Dren Bio with similar companies based on industry and business-model similarity.

Dren Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
UCB
85%
Abcuro
84%
Zenas BioPharma
77%

Dren Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Corporate FundingJul 24, 2024
Series BJun 14, 2022
Series AOct 16, 2020
SeedJul 1, 2019

Key People

Founding team and executive leadership

Amit Mehta

Chief Operating Officer And Chief Business Officer

Executive Team

Dren Bio Investors

Notable investors and investment history

Dren Bio investors
InvestorRounds
Taiho VenturesSeries B, Series A
ArrowMark PartnersSeries B
HBM Healthcare InvestmentsSeries A, Series B
BVF Partners L.P.Series B, Series A
Alexandria Venture InvestmentsSeries B, Series A
Aisling CapitalSeries B
8VCSeries B, Series A, Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 1, 2026

    Launched proprietary platform for developing multispecific antibodies.

  • Apr 1, 2026

    Lead candidate dibotatug (DR-01) is in clinical development.

Dren Bio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Dren Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Dren Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersSan Carlos, California
Employee Range101
Year Founded2019
Last FundingJul 24, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.